British Society for Histocompatibility & Immunogenetics and British Transplantation Society guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation.
Ongoing technological developments in antibody detection and characterisation allowing relative quantitation of HLA-specific antibody levels, combined with crossmatch results, now allow a graded assessment of patient potential donor immunological risk for allotransplantation, rather than a simple 'positive' or 'negative' categorization of crossmatch results. These developments have driven a thorough revision of the British Society for Histocompatibility & Immunogenetics and British Transplantation Society Guidelines for the Detection and Characterisation of Clinically Relevant Antibodies in Allotransplantation. These newly published revised Guidelines contain a number of recommendations as to best practice for antibody detection and crossmatching for the transplantation of a wide range of solid organs and tissues. These recommendations are briefly summarized in this article.
Howell
W M
WM
Department of Histocompatibility and Immunogenetics, NHS Blood and Transplant, Newcastle upon Tyne, UK. martin.howell@nhsbt.nhs.uk
Harmer
A
A
Briggs
D
D
Dyer
P
P
Fuggle
S V
SV
Martin
S
S
Sinnott
P
P
Smith
J
J
Taylor
C J
CJ
Vaughan
R
R
D000906:Antibodies / Q000032:analysis; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology; D016377:Organ Transplantation; D014184:Transplantation, Homologous
D000906:Antibodies; D006680:HLA Antigens